glp 1 patient education GLP-1 Medications Infographic 5 Keys to Patient Education

Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk

Mounjaro showed the highest risk profile, with users experiencing more than a 50% greater likelihood of severe GI issues compared to those taking SGLT-2 inhibitors like Januvia and Farxiga

However, evidence also shows that when GLP-1 medications are stopped, many patients regain much of the weight

Neurogastroenterol Motil 2010;22:664-e203.ArticlePubMed 26

Regardless, they will receive their medications outside of a standard pharmacy

Hashimoto Thyroiditis